|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2010-2-10
|
|
pubmed:abstractText |
Rapid and complete elimination of donor-specific anti-human leukocyte antigen antibodies (DSA) during antibody-mediated rejection (AMR) is rarely achieved with traditional antihumoral therapies. Proteasome inhibitor-based therapy has been shown to effectively treat refractory AMR, but its use as a primary therapy for AMR has not been presented. Our initial experience with proteasome inhibition as a first-line therapy for AMR is presented.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal...,
http://linkedlifedata.com/resource/pubmed/chemical/Boronic Acids,
http://linkedlifedata.com/resource/pubmed/chemical/Creatinine,
http://linkedlifedata.com/resource/pubmed/chemical/HLA Antigens,
http://linkedlifedata.com/resource/pubmed/chemical/Immunologic Factors,
http://linkedlifedata.com/resource/pubmed/chemical/Isoantibodies,
http://linkedlifedata.com/resource/pubmed/chemical/Protease Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Pyrazines,
http://linkedlifedata.com/resource/pubmed/chemical/bortezomib,
http://linkedlifedata.com/resource/pubmed/chemical/rituximab
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
1534-6080
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
15
|
|
pubmed:volume |
89
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
277-84
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:20145517-Adult,
pubmed-meshheading:20145517-Antibodies, Monoclonal,
pubmed-meshheading:20145517-Antibodies, Monoclonal, Murine-Derived,
pubmed-meshheading:20145517-Biopsy,
pubmed-meshheading:20145517-Boronic Acids,
pubmed-meshheading:20145517-Creatinine,
pubmed-meshheading:20145517-Female,
pubmed-meshheading:20145517-Graft Rejection,
pubmed-meshheading:20145517-HLA Antigens,
pubmed-meshheading:20145517-Humans,
pubmed-meshheading:20145517-Immunologic Factors,
pubmed-meshheading:20145517-Immunosuppression,
pubmed-meshheading:20145517-Isoantibodies,
pubmed-meshheading:20145517-Kidney Failure, Chronic,
pubmed-meshheading:20145517-Kidney Transplantation,
pubmed-meshheading:20145517-Protease Inhibitors,
pubmed-meshheading:20145517-Pyrazines,
pubmed-meshheading:20145517-Transplantation, Homologous,
pubmed-meshheading:20145517-Young Adult
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection.
|
|
pubmed:affiliation |
Department of Surgery, Division of Transplantation, University of Cincinnati College of Medicine, Cincinnati, OH 45267, USA.
|
|
pubmed:publicationType |
Journal Article,
Case Reports,
Research Support, Non-U.S. Gov't
|
